Table 4.

Current status of selected drugs for pediatric brain cancer.

S. No.	Drug	Developer	Country of Origin	Rationale of Use	Current Status	References
1.	Dabrafenib	Pediatric Oncology Unit, UCL Great Ormond Street Institute of Child Health, London, United Kingdom	London, United Kingdom	In low-grade gliomas	Phase I/II trial	[230]
2.	Vemurafenib	Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA	San Francisco, CA, USA	Metastatic melanoma	Phase I	[231]
3.	Indoximod	Augusta University, Georgia Cancer Center	Georgia, United States	Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma	Phase 2	[232]
4.	MGMT(P140K)gene therapy	Children’s Cancer Research Unit, Kid’s Research Institute, The Children’s Hospital at Westmead, NSW, Australia	Australia	Pediatric brain tumor	Phase I	[233]
5.	Procarbazine, lomustine and vincristine	Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA	Kentucky, USA	High-grade glioma	Phase I	[234]
6.	Nelarabine	Carilion Clinic, Pediatrics, Roanoke	USA	T-cell Malignancy	Phase 2	[235]
7.	Blinatumomab	Johns Hopkins University, Department of Oncology, Baltimore, USA	USA	Pediatric B-Precursor Acute Lymphoblastic Leukemia (B-ALL)	Phase 3	[236]
8.	Quinapril	St. Jude Children's Research Hospital, Pathology, Memphis, USA	USA	Acute Lymphoblastic Leukemia	Phase 1	[237]
9.	Mafosfamide	Departments of Pediatrics, Neurosurgery, Neuropathology and Radiotherapy, University of Vienna, Vienna, Austria	Austria	Embryonal tumors	Phase 1	[238]
10.	Volasertib	Institute Curie and University Paris Descartes, Pediatric, Adolescent and Young Adults Oncology Department, Paris, France	Paris, France	Acute Leukemia and Advanced Solid Tumors	Phase 1	[239]